This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (40)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Tobacco  • Drug Therapy, Other  • Alert me on articles by topic

Cheryl Oncken, MD; David Gonzales, PhD; Mitchell Nides, PhD; Stephen Rennard, MD; Eric Watsky, MD; Clare B. Billing, MS; Richard Anziano, MS; Karen Reeves, MD; for the Varenicline Study Group

Arch Intern Med. 2006;166:1571-1577.

Background  The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.

Methods  This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide–confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.

Results  Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation.

Conclusion  Varenicline tartrate, 0.5 mg and 1.0 mg twice daily, is efficacious for smoking cessation.

Author Affiliations: University of Connecticut Health Center, Farmington (Dr Oncken); Oregon Health & Science University, Portland (Dr Gonzales); Los Angeles Clinical Trials, Los Angeles, Calif (Dr Nides); University of Nebraska Medical Center, Omaha (Dr Rennard); and Pfizer Global Research and Development, Groton, Conn (Drs Watsky and Reeves and Ms Billing and Mr Anziano).

RELATED ARTICLES

New Weapon to Curb Smoking: No More Excuses to Delay Treatment
Bankole A. Johnson
Arch Intern Med. 2006;166(15):1547-1550.
EXTRACT | FULL TEXT  

Cytisine for Smoking Cessation: A Literature Review and a Meta-analysis
Jean-François Etter
Arch Intern Med. 2006;166(15):1553-1559.
ABSTRACT | FULL TEXT  

Smoking Cessation With Varenicline, a Selective 42 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell Nides, Cheryl Oncken, David Gonzales, Stephen Rennard, Eric J. Watsky, Rich Anziano, Karen R. Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1561-1568.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Varenicline-Associated Acute Renal Failure
Bird and Vesta
The Annals of Pharmacotherapy 2008;42:1908-1911.
ABSTRACT | FULL TEXT  

Varenicline for Tobacco Dependence
Hays and Ebbert
NEJM 2008;359:2018-2024.
FULL TEXT  

Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
Pirmoradi et al.
Am J Health Syst Pharm 2008;65:1624-1626.
ABSTRACT | FULL TEXT  

Smoking: A Deadly Pleasant Habit--Is There a Way Out?
Richter
ANGIOLOGY 2008;59:49S-53S.
ABSTRACT  

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg et al.
CMAJ 2008;179:135-144.
ABSTRACT | FULL TEXT  

Update on pharmacologic and nonpharmacologic therapies for smoking cessation
Schmelzle et al.
cfp 2008;54:994-999.
ABSTRACT | FULL TEXT  

{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT | FULL TEXT  

Hypomania with Agitation Associated with Varenicline Use in Bipolar II Disorder
Morstad et al.
The Annals of Pharmacotherapy 2008;42:288-289.
FULL TEXT  

Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT  

Another Arrow in the Quiver to Combat Smoking
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT  

New Weapon to Curb Smoking: No More Excuses to Delay Treatment.
Johnson
Arch Intern Med 2006;166:1547-1550.
FULL TEXT